In vivo ameliorative effect of methanolic extract of Boswellia dalzielli Hutch (Mebdh) stem bark on Triton X-100 induced hyperlipidaemia
Hyperlipidemia is a major risk factor for coronary heart diseases and ischemia that leading to high rates of mortalities. Conventionally, hyperlipidemia is managed using agents that facilitate the clearance of total cholesterol (TC), triacylglycerides (TAG) and low density lipoprotein (LDL) from the body. Despite the use of these drugs, the disease still remained a global burden that affects the quality of life. The current study was done to investigate hypolipidemic properties of the methanolic extract of Boswellia dalzielli hutch (MEBDH) stem bark in rodents. The phytochemicals of the MEBDH were screened and determined qualitatively before performing acute toxicity study to determine the LD50 of the extract. Twenty five male albino rats 2-3 months old (150-210) g were distributed randomly into five groups [Group 1: normal control received 200 μL normal saline daily for 3 weeks, Group 2: hyperlipidemic control induced by a single dose of Triton X-100 (150 mg/kg body weight) subcutaneously, followed by oral administration of 200 μL normal saline daily for 3 weeks. Group 2 and 4: hyperlipidemic rats treated orally with MEBDH (200 and 400 mg/kg body weight) respectively for 21 days. Group 5: hyperlipidemic rats treated with Simvastatin (5 mg/kg body weight) daily throughout the experimental period as positive control]. Administration of the extract did not cause any mortality regardless of the dose. However, the extract caused significant (p<0.05) decrease in TC, TAG and LDL-cholesterol levels in the treated rats. The decrease observed is significantly lower than that of untreated rats. In contrast, the level of HDL increased significantly (p<0.05) after treating the rats with the MEBDH stem bark. The extract of MEBDH possessed hypolipidemic agents and could be the potential substitute hyperlipidemic agents with side effect.
Keywords: Albino Rats, Atherosclerosis, Boswellia dalzielli hutch, Coronary Heart Disease, Hyperlipidemia, Triton X100